These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11378012)

  • 1. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
    Louis A; Cleland JG; Crabbe S; Ford S; Thackray S; Houghton T; Clark A
    Eur J Heart Fail; 2001 Jun; 3(3):381-7. PubMed ID: 11378012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.
    Clark AL; Coats AJS; Krum H; Katus HA; Mohacsi P; Salekin D; Schultz MK; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):549-556. PubMed ID: 28244261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of carvedilol in atrial fibrillation: insights from clinical trials.
    Gheorghiade M; Lukas MA
    Am J Cardiol; 2004 May; 93(9A):53B-7B. PubMed ID: 15144939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MI.
    Coats AJ
    Int J Cardiol; 2001 Apr; 78(2):109-13. PubMed ID: 11334653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.
    Coletta AP; Clark AL; Seymour AM; Cleland JG
    Eur J Heart Fail; 2003 Aug; 5(4):545-8. PubMed ID: 12921817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol: a review of its use in chronic heart failure.
    Keating GM; Jarvis B
    Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
    Sackner-Bernstein JD
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S25-9. PubMed ID: 14564231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of carvedilol arrhythmia data in clinical trials.
    Kowey PR
    J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S59-68. PubMed ID: 15965573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effectiveness of carvedilol in heart failure].
    Kárpáti K; Brodszky V; Farsang C; Jermendy G; Vándorfi G; Zámolyi K; Gulácsi L
    Orv Hetil; 2006 Oct; 147(40):1931-7. PubMed ID: 17111685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol saves lives--new data from landmark trials prove survival benefits in heart failure and post myocardial infarction.
    Cardiovasc J S Afr; 2001; 12(2):122-3. PubMed ID: 11474697
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART.
    Witte K; Thackray S; Clark AL; Cooklin M; Cleland JG
    Eur J Heart Fail; 2000 Dec; 2(4):455-60. PubMed ID: 11113724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
    Fowler MB
    Am J Cardiol; 2004 May; 93(9A):35B-9B. PubMed ID: 15144935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
    Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
    Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
    Opasich C; De Feo S; Cioffi G; Pulignano G; Del Sindaco D; Tarantini L; Gualco A; Patrignani A
    Ital Heart J; 2005 Apr; 6(4):323-7. PubMed ID: 15902931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beta blockers in post-infarction state].
    Schultheiss HP; Tschöpe C
    Herz; 2002 Aug; 27 Suppl 1():26-9. PubMed ID: 12229255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
    Rouleau JL; Roecker EB; Tendera M; Mohacsi P; Krum H; Katus HA; Fowler MB; Coats AJ; Castaigne A; Scherhag A; Holcslaw TL; Packer M;
    J Am Coll Cardiol; 2004 Apr; 43(8):1423-9. PubMed ID: 15093878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure].
    Zaikin SY; Iosava IK; Vasechkin SS; Gruzdev AK; Sidorenko BA
    Kardiologiia; 2002; 42(4):33-6. PubMed ID: 12494164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.